Overall rank by patents
#25,292
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 8 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
The verdict
Standard holds 11 US patents across 8 technology areas, rank #25,292 of 50,000 tracked assignees.
Standard Biotools Canada Inc. has been granted 11 US utility patents between 2023 and 2025, placing Standard Biotools Canada Inc. at rank #25,292 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.6 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, Standard Biotools Canada Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Standard sits between Spiral Therapeutics, Inc. (11 patents, rank #25,288) and Starpharma Pty Ltd. (11 patents, rank #25,296) - the closest US assignees by grant volume. The composite Innovation Score of 51.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Standard Biotools Canada Inc.'s 21.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Standard Biotools Canada Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Spiral Therapeutics, Inc.
11 patents
Spookfish Innovations PTY LTD
11 patents
Sprout Pharmaceuticals, Inc.
11 patents
Spühl GmbH
11 patents
Standard Energy Inc.
11 patents
Stanley Works (Europe) GmbH
11 patents
Starbuzz® Tobacco, Inc.
11 patents
Starpharma Pty Ltd.
11 patents
Standard BioTools Canada Inc.
11 patents
What this shows Standard holds 11 patents at rank #25,292, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Standard's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
52 Top 11% higher than 89% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 2 | 18.2% |
| 2024 | 6 | 54.5% |
| 2025 | 3 | 27.3% |
Top 8 of 8 technology areas
Overall rank by patents
#25,292
Across all tracked assignees
51.6 out of 100
How to use this portfolio
Standard's 11 grants land it in the top 11% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.